CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Pharmaceutical Group Limited has announced that their new antihypertensive drug, Valsartan Levoamlodipine Maleate Tablets, has received approval from China’s National Medical Products Administration to begin clinical trials. This novel compound, combining valsartan and levoamlodipine maleate, targets mild to moderate hypertension and offers potential benefits in efficacy and safety over monotherapy treatments.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
